Evidence map›Paper›PMID 42624075›Full record

ReviewCell2026

Neurodegeneration as a dysregulation of neuroimmune crosstalk.

F Chris Bennett, Soyon Hong, Ning Jiang, Ivan Marazzi

Abstract readReview
In one paragraph

Review in Cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

F Chris BennettDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Neurology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Electronic address: frederick.bennett@pennmedicine.upenn.edu.
Soyon HongUK Dementia Research Institute, Institute of Neurology, University College London, London, UK. Electronic address: soyon.hong@ucl.ac.uk.
Ning JiangDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology and Immune Health, University of Pennsylvania, Philadelphia, PA, USA; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA; Abramsom Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; Institute for RNA Innovation, University of Pennsylvania, Philadelphia, PA, USA; Center for Precision Engineering for Health, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: jnjiang@seas.upenn.edu.
Ivan MarazziDepartment of Biological Chemistry, University of California, Irvine, Irvine, CA, USA; Center for Epigenetics and Metabolism, University of California, Irvine, Irvine, CA, USA. Electronic address: imarazzi@uci.edu.

Funding

Center for Modeling Non-Coding Disease Variants: Resource and Service CoreU54OD039864 · OD · UNIVERSITY OF CALIFORNIA-IRVINE · PI Evgeny Kvon · 2025 to 2026
$5.5M
Role of Adaptive Immunity in Etiology of Alzheimer’s Disease andAlzheimer’s Disease-Related DementiasR01AG078814 · NIA · CHILDREN'S HOSP OF PHILADELPHIA · PI Douglas C Wallace · 2022 to 2026
$4.2M
Regulation of inflammatory gene expression during SARS2 infectionR01AI168130 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI Ivan Marazzi · 2022 to 2026
$3.7M
Characterization of Antigen-Specific Immune Response in ALSRF1NS142171 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ELYAMAN, WASSIM, JIANG, NING JENNY · 2025 to 2025
$3.2M
Amyloid Beta CAR Macrophages: a cell engineering strategy to clear pathogenic proteinsR01NS129737 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI Frederick Bennett, Saar Gill · 2023 to 2026
$2.8M
T cell Immunity in a Rare Juvenile Form of Motor Neuron DiseaseR01NS123287 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI Laura Campisi, Ivan Marazzi · 2023 to 2026
$2.6M
Microglia replacement using engineered HSCs for treatment of leukodystrophiesR01NS136487 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI Frederick Bennett, HANS-PETER KIEM · 2025 to 2026
$1.4M
Decoding antigen specific T cells in frontotemporal degenerationR21AG099004 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Ning Jenny Jiang · 2026 to 2026
$425k
NIAID NIH HHS R01 AI168130NIA NIH HHS R01 AG078814NIA NIH HHS R21 AG099004NIH HHS U54 OD039864NINDS NIH HHS R01 NS123287NINDS NIH HHS R01 NS129737NINDS NIH HHS R01 NS136487NINDS NIH HHS RF1 NS142171Wellcome Trust
6 · The paper itself

Abstract

Neurodegeneration is increasingly recognized not only as a disorder of neurons but also as a breakdown of dialogue between the nervous and immune systems. Recent discoveries reveal that immune cells and inflammatory signals are deeply interwoven with brain function across the lifespan. Far from passive responders, immune cells act as sentinels and shapers of neuronal resilience, vulnerability, and repair. Together, robust data support a model in which neurodegeneration emerges from complex interactions between neural and immune networks, positioning the immune system as both a sensor and driver of brain health. This perspective synthesizes a growing body of work arguing that neurodegenerative diseases are a failure of neuroimmune crosstalk-where protective signals are lost, and maladaptive responses take hold. By restoring immune homeostasis, fine-tuning inflammatory responses, or targeting epigenetic regulators of the immune state, it may be possible not only to slow degeneration but also to promote recovery. We outline the key challenges and opportunities for this paradigm shift and highlight how a deeper integration of neuroscience and immunology could transform the future of treating neurodegenerative diseases. Lastly, we describe critical focus areas to improve our understanding of neurodegeneration and highlight the development of immune-based therapeutics for neurodegeneration.

Indexed as

Neurodegenerative DiseasesNeuroimmunomodulationAnimalsBrainHumansImmune SystemNeurons

Identifiers

PMID42624075
PMCPMC13592536

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.